journal article
Download Only Collection
Home
Prochazka, Katharina T.; Neumeister, Peter
2021 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-021-00735-zpmid: 34394761
Summary In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give an overview on updated onkopedia guidelines, studded with updates of the landmark studies of the latest American Society of Hematology (ASH) meeting. In addition, since still crucial, recommendations concerning coronavirus disease 2019 (COVID-19) in chronic lymphocytic leukaemia patients will be covered.
2021 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-021-00725-1
Summary At the 62nd annual meeting of the American Society of Hematology (ASH) 2020—which took place virtually for the first time—numerous clinical studies and research results were presented. The latest trends and exciting developments in the field of stem cell transplantation can be found in the following article, e. g. how transplantations with a mismatch donor can be safely performed, important studies regarding MDS and ALL patients, a promising second-line treatment in chronic GVHD, why the nutritional status and the microbiome should be part of the pre-transplant work-up and that lifelong follow-up for children and young adolescents after an allogeneic transplantation is essential.
2021 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-021-00746-w
Summary The meeting focused in particular on new strategies such as chimeric antigen receptor (CAR)-T cells and bispecific antibodies. Updates of clinical trials regarding induction treatment in transplantable and non-transplantable status were presented. Furthermore, minimal residual disease negativity (MRD) or, in other words, a status characterized by no measurable disease, using standardized multicolor-flow cytometry or next-generation sequencing techniques becomes increasingly important as an endpoint in clinical trials. A subjectively assessed overview of the current contributions to the treatment of multiple myeloma is given here.
2021 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-020-00669-ypmid: 33362882
Summary Background Multiple myeloma (MM) is a cytogenetically heterogeneous and incurable plasma cell disease with unknown etiology. It is thought that the ABO blood groups may play a role in the etiology of many diseases. The purpose of this study is to determine whether there is a relationship between the ABO blood groups and the development of MM, clinical findings and overall survival. Methods In this single-center, retrospective and observational study, 198 patients with known blood types who diagnosed with MM between January 2012 and June 2020 were included. Results It was shown that individuals with blood group 0 had a significantly lower risk of MM (OR = 0.575, 95% confidence interval 0.416–0.794, P = 0.001). The incidence of extramedullary lesion was significantly higher in those with 0 blood group compared to other blood groups (P = 0.000). Overall survival was significantly shorter in patients with 0 blood group than those without 0 blood group (P = 0.007). Conclusion Individuals with 0 blood group had a lower risk of developing MM. It was determined that having 0 blood group is a predisposing factor for the development of extramedullary lesion in MM patients. However, it was shown that having a blood group of 0 was a very significant prognostic factor for MM patients and was associated with short OS.
Showing 1 to 10 of 26 Articles